Results 71 to 80 of about 5,598,449 (384)

Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities

Molecular Oncology, EarlyView.
Urine is a rich source of biomarkers for cancer detection. Tumor‐derived material is released into the bloodstream and transported to the urine. Urine can easily be collected from individuals, allowing non‐invasive cancer detection. This review discusses the rationale behind urine‐based cancer detection and its potential for cancer diagnostics ...
Birgit M. M. Wever, Renske D. M. Steenbergen   +1 more
wiley   +1 more source

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review

BJUI Compass
Objective To analyse the latest evidence on the relative harms and benefits of screening and diagnostic pathways with close examination of (i) men aged 50 years or older, (ii) men whose ethnicity places them at higher risk and (iii) men with a family ...
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2018
Prostate cancer often develops resistance to androgen receptor (AR) targeting drugs. Here, the authors show that, under conditions of hypoxia, AR inhibition via enzalutamide increases the expression of the glycolytic enzyme phosphoglucose isomerase (GPI)
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Nature Communications, 2021
The prognosis of castration-resistant prostate cancers remains dismal, but accurate preclinical models can lead to effective therapies. Here the Melbourne Urological Research Alliance establish prostate cancer patient-derived xenografts, use the tumors ...
Gail P. Risbridger, Ashlee K. Clark, Laura H. Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L. Lister, David Pook, Carmel J. Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B. Madsen, Hong Wang, Michelle G. Richards, Birunthi Niranjan, Samantha O’Dea, Linda Teng, William Wheelahan, Zhuoer Li, Nicholas Choo, John F. Ouyang, Heather Thorne, Lisa Devereux, Rodney J. Hicks, Shomik Sengupta, Laurence Harewood, Mahesh Iddawala, Arun A. Azad, Jeremy Goad, Jeremy Grummet, John Kourambas, Edmond M. Kwan, Daniel Moon, Declan G. Murphy, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Luc Furic, David L. Goode, Mark Frydenberg, Mitchell G. Lawrence, Renea A. Taylor   +44 more
doaj   +1 more source

Rapid progression of prostate cancer in men with a BRCA2 mutation. [PDF]

, 2008
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients.
Ainsworth, Peter, Armel, S, Bellati, Christina, Couch, F, Cummings, S, Daly, Mary, Danquah, Jessica, Domchek, Susan, Eisen, Andrea, Foulkes, WD, Garber, Judy, Ghadirian, P, Gilchrist, Dawna, Hereditary Breast Cancer Study Group, Horsman, Douglas, Isaacs, Claudine, Karlan, Beth, Kim-Sing, Charmaine, Lynch, HT, Manoukian, Siranoush, Maugard, Christine, McKinnon, Wendy, Meschino, Wendy, Nam, R, Narod, SA, Nedelcu, Raluca, Neuhausen, S, Olopade, O, Pasini, Barbara, Poll, A, Saal, H, Stoppa-Lyonnet, D, Sun, P, Tulman, A, Tung, Nadine, Vichodez, G, Wagner, T, Warner, E, Weitzel, J, Wood, Marie   +39 more
core  

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial [PDF]

, 2016
BACKGROUND: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA ...
Barber, John R, De Marzo, Angelo M, Drake, Charles G, Goodman, Phyllis J, Gurel, Bora, Kristal, Alan R, Lippman, Scott M, Lucia, M. Scott, Murtola, Teemu J, Nelson, William G, Parnes, Howard L, Peskoe, Sarah B, Platz, Elizabeth A, Sutcliffe, Siobhan, Thompson, Ian M, Jr., Umbehr, Martin   +15 more
core   +2 more sources

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative. [PDF]

, 2017
BackgroundEvidence suggests that risk of colorectal and prostate cancer is increased among those with a family history of the same disease, particularly among first-degree relatives.
Beebe-Dimmer, Jennifer L, Bock, Cathryn H, Lane, Dorothy, Nassir, Rami, Palmer, Nynikka RA, Paskett, Electra, Schwartz, Ann G, Simon, Michael S, Yee, Cecilia   +8 more
core   +2 more sources

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Feasibility of radical cardiac‐sparing, treatment planning strategies for patients with locally advanced, non‐small cell lung cancer

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non‐small cell lung cancer (NSCLC) patients in order to minimize cardiac dose without compromising target coverage goals. Methods Retrospective analysis was performed for 20 NSCLC patients prescribed to 60–66 Gy that received a ...
Joshua P. Kim, Jake Dewalt, Aharon Feldman, Khaled Adil, Benjamin Movsas, Indrin J. Chetty   +5 more
wiley   +1 more source